Biora Therapeutics completed an agreement with a large diagnostics company for the sale of legacy assets related to Biora’s former diagnostics business. Biora Therapeutics will receive a one-time payment for the sale of assets including rights to certain antibody sequences. Specific terms of the agreement were not disclosed.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIOR:
- Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
- Biora Therapeutics announces new patents for its NaviCap platform
- Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
- Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
- Biora presents data on BioJet Oral Biotherapeutic Delivery Platform